BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10. Following the sale, the chief accounting officer owned 123,945 shares of the company's stock, valued at $9,210,352.95. The trade was a 0.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Maricel Apuli also recently made the following trade(s):
- On Monday, December 8th, Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.26, for a total transaction of $148,520.00.
BridgeBio Pharma Stock Performance
Shares of NASDAQ:BBIO opened at $73.93 on Thursday. The firm has a market cap of $14.25 billion, a PE ratio of -17.69 and a beta of 1.13. The firm's 50 day simple moving average is $75.73 and its 200-day simple moving average is $63.79. BridgeBio Pharma, Inc. has a one year low of $28.33 and a one year high of $84.94.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Barclays assumed coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They set an "overweight" rating for the company. The Goldman Sachs Group lifted their price objective on BridgeBio Pharma from $55.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, October 30th. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a report on Thursday, December 11th. They set an "outperform" rating and a $94.00 target price on the stock. HC Wainwright raised their target price on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Piper Sandler boosted their price target on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an "overweight" rating in a report on Thursday, October 30th. Twenty-two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $82.05.
View Our Latest Research Report on BridgeBio Pharma
BridgeBio Pharma News Summary
Here are the key news stories impacting BridgeBio Pharma this week:
- Positive Sentiment: Strong Phase 3 PROPEL 3 results in achondroplasia — a major clinical readout that improves the drug candidate’s regulatory and commercial outlook and is a clear fundamental upside driver for BBIO. PROPEL 3 Results
- Positive Sentiment: HC Wainwright boosted its price target to $100 and raised near‑term EPS estimates across Q2–Q4 and FY2026, reaffirming a Buy stance — analyst upgrades add conviction for longer‑term upside. HC Wainwright PT Raise
- Positive Sentiment: Broad analyst support remains strong (many Buy/Overweight ratings and median targets well above current levels), providing aftermarket analyst‑driven demand if clinical and financials meet expectations. Analyst Coverage Summary
- Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this scheduled event can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
- Neutral Sentiment: Company granted inducement RSUs to 34 new hires (76,701 shares aggregate) — modest near‑term share‑based compensation and potential future dilution to monitor. Inducement Grants
- Neutral Sentiment: Oppenheimer added a small new position (7,845 shares) per 13F — modest institutional buying that is not yet material but shows some investor interest. Oppenheimer 13F
- Negative Sentiment: Clustered insider selling on Feb. 17 — Director Randal W. Scott sold 10,000 shares (~$754k) and other senior officers (including the CFO and CAO) filed sales the same day; concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
- Negative Sentiment: Data providers and reporting highlight a history of executive selling — ongoing insider liquidity events can keep downward pressure on the stock until company insiders rebuild meaningful insider ownership. Insider/Sentiment Summary
Institutional Trading of BridgeBio Pharma
A number of institutional investors have recently bought and sold shares of BBIO. Corient Private Wealth LLC acquired a new stake in shares of BridgeBio Pharma in the second quarter worth approximately $643,000. WINTON GROUP Ltd purchased a new position in BridgeBio Pharma in the 2nd quarter valued at $3,856,000. Principal Financial Group Inc. boosted its stake in BridgeBio Pharma by 23.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company's stock worth $65,829,000 after purchasing an additional 236,885 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of BridgeBio Pharma by 53.0% during the third quarter. Federated Hermes Inc. now owns 424,695 shares of the company's stock worth $22,059,000 after buying an additional 147,108 shares in the last quarter. Finally, Bosun Asset Management LLC grew its holdings in shares of BridgeBio Pharma by 119.7% during the second quarter. Bosun Asset Management LLC now owns 26,154 shares of the company's stock worth $1,129,000 after buying an additional 14,250 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
